Research progress of opioid growth factor in immune-related diseases and cancer diseases

2021 ◽  
Vol 99 ◽  
pp. 107713
Author(s):  
Hai Huang ◽  
Bing Liu ◽  
Na Qu ◽  
Shuling Zhang ◽  
Xueli Bai ◽  
...  
Keyword(s):  
Growth Factor ◽  
Research Progress ◽  
Opioid Growth Factor ◽  
Cancer Diseases

Opioid growth factor and its derivatives as potential non-toxic multifunctional anticancer and analgesic compounds

2020 ◽  
Vol 27 ◽  
Author(s):  
Justyna Budka ◽  
Szymon Kowalski ◽  
Monika Chylinska ◽  
Krystyna Dzierzbicka ◽  
Iwona Inkielewicz-Stepniak
Keyword(s):  
Growth Factor ◽  
Anticancer Drugs ◽  
Research Progress ◽  
Immunomodulatory Activity ◽  
Opioid Growth Factor ◽  
Treatment And Prevention ◽  
Significant Research ◽  
Important Challenge ◽  
Prevention Of Cancer ◽  
Preclinical And Clinical Studies

: Despite significant research progress on the pathogenesis, molecular biology, diagnosis, treatment, and prevention of cancer its morbidity and mortality is still high around the world. The emerging resistance of cancer cells to anticancer drugs remains still a significant problem in oncology today. Furthermore, an important challenge is the inability of anticancer drugs to selectively target tumor cells thus sparing healthy cells. One of new potential options for efficient and safe therapy can be provided by opioid growth factor (OGF), chemically termed Met-enkephalin. It is an endogenous pentapeptide (Tyr-Gly-Gly-Phe-Met) with antitumor, analgesic and immune-boosting properties. Clinical trials have demonstrated that OGF therapy alone, as well as in combination with standard chemotherapies, is a safe, non-toxic anticancer agent that reduces tumor size. In this paper, we review the structure-activity relationship of OGF and its analogues. We highlight also OGF derivatives with analgesic, immunomodulatory activity and the ability to penetrate the blood-brain barrier and may be used as a safe agents enhancing chemotherapy efficacy and improving quality of life in cancer patients. The reviewed papers indicate that Met-enkephalin, as well as its analogues are interesting candidates for the development of novel, non-toxic and endowed with an analgesic activity anticancer drugs. More preclinical and clinical studies are needed to explore these opportunities.

Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse

2000 ◽  
Vol 84 (1-2) ◽  
pp. 106-114 ◽  
Author(s):  
Ian S Zagon ◽  
Michael F Verderame ◽  
Warren E Zimmer ◽  
Patricia J McLaughlin
Keyword(s):  
Growth Factor ◽  
Molecular Characterization ◽  
Growth Factor Receptor ◽  
Opioid Growth Factor

scholarly journals The Opioid Growth Factor (OGF)–OGF Receptor Axis Uses the p16 Pathway to Inhibit Head and Neck Cancer

2007 ◽  
Vol 67 (21) ◽  
pp. 10511-10518 ◽  
Author(s):  
Fan Cheng ◽  
Ian S. Zagon ◽  
Michael F. Verderame ◽  
Patricia J. McLaughlin
Keyword(s):  
Head And Neck Cancer ◽  
Growth Factor ◽  
Head And Neck ◽  
Neck Cancer ◽  
Opioid Growth Factor

The autocrine derivation of the opioid growth factor, [Met5]-enkephalin, in ocular surface epithelium

1998 ◽  
Vol 792 (1) ◽  
pp. 72-78 ◽  
Author(s):  
Ian S Zagon ◽  
Joseph W Sassani ◽  
Yan Wu ◽  
Patricia J McLaughlin
Keyword(s):  
Growth Factor ◽  
Ocular Surface ◽  
Surface Epithelium ◽  
Opioid Growth Factor ◽  
Ocular Surface Epithelium

scholarly journals Regulation of Tenon's Capsule Fibroblast Cell Proliferation by the Opioid Growth Factor and the Opioid Growth Factor Receptor Axis

2010 ◽  
Vol 51 (10) ◽  
pp. 5054 ◽  
Author(s):  
Matthew S. Klocek ◽  
Joseph W. Sassani ◽  
Renee N. Donahue ◽  
Patricia J. McLaughlin ◽  
Ian S. Zagon
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Fibroblast Cell ◽  
Opioid Growth Factor ◽  
Tenon’S Capsule ◽  
Tenon's Capsule
Sign in / Sign up

Export Citation Format

Share Document